Immunogenicity, Efficacy and Safety of Covishield vaccine in Non- dialysis Chronic Kidney Disease Patients in Comparison with Healthy Subjects; A Clinical Cohort Study

Background: The incidence of chronic kidney disease (CKD) is more than ten percent globally and they show higher mortality with COVID-19. The immune response of CKD patients to Covishield vaccine may vary. Therefore, understanding vaccine efficacy in this population is critical. Aim: To compare the immunogenicity, safety and efficacy of Covishield vaccine in Non-Dialysis CKD patients with healthy subjects. Methods: Non dialysis CKD patients represent Cohort one and healthy participants represent cohort two. Eligible participants were recruited between 21 and 90 days post second dose of Covishield vaccination. IgG and IFN gamma levels were measured to assess immunogenicity. Any adverse effects were documented in an Adverse Event Following Immunization form through direct or telephonic interview. The occurrence of COVID-19 illness was used to assess efficacy. Data analysis was done by using t-tests and Chi-square tests. Results: We recruited 40 non-dialysis CKD patients and 38 healthy participants. IgG (p = 0.072) and IFN gamma levels (p = 0.339) were not statistically different between these groups. The ADR profile was also similar between the two groups. None of the participants developed COVID-19 illness during the study period. Conclusion: Non-dialysis CKD patients showed similar immunogenicity, safety, and efficacy to the Covishield vaccine as compared to healthy participants. Hence, non-dialysis CKD patients can follow the routine vaccination schedule.